Allergies are becoming increasingly common, and the prevalence of allergies is rising globally. This is driving demand for allergy immunotherapy products as more people seek effective treatments for their allergies. Moreover, personalized medicine is an important trend in the healthcare industry, and this is also true for allergy immunotherapy. As more patients seek personalized treatment options, the demand for customized allergy immunotherapy products is increasing. Furthermore, technology is playing a critical role in the development of new allergy immunotherapy products. For example, advances in genetic testing and biotechnology are helping to identify new allergens and develop more targeted and effective treatments.
The allergy immunotherapy market is becoming increasingly competitive, with many new players entering the market. Established players are investing heavily in research and development to develop new and innovative products and gain a competitive edge.
The global Allergy Immunotherapy Market was valued at US$ 2,116.0 million in 2022 and is expected to exhibit a CAGR of 9.3% over the forecast period (2022-2030).
Prominent Companies in the Allergy Immunotherapy Industry:
1. Stallergenes Greer: Stallergenes Greer is a global biopharmaceutical company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 1959 and is headquartered in London, UK. Stallergenes Greer announced in February 2023 that it had completed the acquisition of a Canadian biotech company called AllergyTherapeutics. This acquisition is expected to strengthen Stallergenes Greer's position in the global allergy immunotherapy market, as AllergyTherapeutics is a leading developer of allergy immunotherapy products in Europe.
2. ALK-Abello A/S: ALK-Abello A/S is a Danish pharmaceutical company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 1923 and is headquartered in Hørsholm, Denmark. ALK-Abello A/S announced in January 2023 that it had received regulatory approval from the European Medicines Agency (EMA) for its new sublingual allergy immunotherapy tablet, called ACARIZAX. This tablet is designed to treat house dust mite allergies, which are a common cause of respiratory allergies.
3. Allergy Therapeutics: Allergy Therapeutics is a UK-based biotechnology company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 1999 and is headquartered in Worthing, UK. Allergy Therapeutics was acquired by Stallergenes Greer in February 2023. Moreover, in December 2022, the company announced positive results from a Phase IIb clinical trial of its adjuvant-free, high-dose subcutaneous immunotherapy (SCIT) product for the treatment of grass pollen allergies. The study found that the product was safe and effective in reducing patients' allergy symptoms compared to placebo.
4. Allergopharma: Allergopharma is a German pharmaceutical company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 1969 and is headquartered in Reinbek, Germany. Allergopharma announced in September 2021 that it had received approval from the European Medicines Agency (EMA) for its new subcutaneous allergy immunotherapy product, called Acarovac Plus. This product is designed to treat house dust mite allergies, which are a common cause of respiratory allergies.
5. HAL Allergy Group: HAL Allergy Group is a Dutch pharmaceutical company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 1959 and is headquartered in Leiden, the Netherlands. HAL Allergy Group was acquired by Anergis SA, a Swiss-based biotechnology company specializing in the development of allergy immunotherapy products, in November 2021. The acquisition is expected to strengthen Anergis' position in the allergy immunotherapy market and expand its product portfolio.
6. Aimmune Therapeutics: Aimmune Therapeutics is a US-based biopharmaceutical company that specializes in the development and commercialization of treatments for food allergies. The company was founded in 2011 and is headquartered in Brisbane, California. In October 2022, Aimmune Therapeutics announced positive results from a Phase II clinical trial of a new egg allergy immunotherapy product called AIMu-TEC001. The product uses a novel approach called T-cell epitope-containing (TEC) peptides to train the immune system to recognize and tolerate egg proteins.
7. DBV Technologies: DBV Technologies is a French biopharmaceutical company that specializes in the development of treatments for food allergies. The company was founded in 2002 and is headquartered in Montrouge, France. In October 2021, DBV Technologies announced positive results from a Phase III clinical trial of Viaskin Peanut in children aged 1 to 3 years with peanut allergy.
8. Leti Pharma: Leti Pharma is a Spanish biotechnology company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 2000 and is headquartered in Madrid, Spain. Leti Pharma announced the launch of a new sublingual allergy immunotherapy product for grass pollen allergy in Spain and Italy in October 2021. The product, called LetiFend Grass, is a fast-dissolving tablet that contains a standardized extract of grass pollen and is designed to reduce patients' allergy symptoms.
9. Jubilant HollisterStier: Jubilant HollisterStier is a US-based biopharmaceutical company that specializes in the development and manufacture of allergy immunotherapy products. The company was founded in 1907 and is headquartered in Spokane, Washington. Jubilant HollisterStier announced the acquisition of a new production facility in Montreal, Canada, in March 2022. The facility is equipped with state-of-the-art technology and will allow the company to expand its production capabilities for allergy immunotherapy products, as well as other pharmaceuticals.
Definition: Allergy immunotherapy is a medical treatment that involves exposing an individual with allergies to small, gradually increasing doses of an allergen over a period of time in order to reduce or eliminate the allergic response to that allergen.
